|Day Low/High||8.17 / 8.80|
|52 Wk Low/High||5.01 / 18.87|
With lockdowns ending and life as we knew it resuming to some extent, these three stocks should benefit.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
This stock market is doing a nice job of making it tough on everyone.
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
This is a battleground stock that has made big moves in both directions on earnings in the past.
If you are interested in Square longer term be patient and wait for the drama to end.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
The indices are hitting highs as the market shrugs off yesterday's rotation.
I'm looking for some new entries in less-speculative names, but many stocks need a rest at this point.
I'm always excited about the potential for new trades when we have selling like this.
The housing market will continue to improve over the next few years due to pent up demand.
Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.
The first part of Flexion's decline can be attributed to some profit taking.
The Burlington, Mass.-based firm announced a proposed public offering of 4 million shares. It plans to use part of the net proceeds to fund manufacturing and commercialization of osteoarthritis knee pain treatment Zilretta.
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
The Boston firm said microbiology data show that investigational antibiotic omadacycline is 'active against the clinically important typical and atypical community-acquired bacterial pneumonia (CABP) pathogens.'